Sarep­ta rais­ing $325M; Astel­las joins the big mi­gra­tion to Cam­bridge, MA

With its shares boost­ed by news of swelling rev­enue from its eteplirsen fran­chise in Duchenne mus­cu­lar dy­s­tro­phy, Sarep­ta has priced shares $SRPT for a $325 mil­lion raise. The biotech says it plans to use the cash for a va­ri­ety of pur­pos­es, rang­ing from com­mer­cial­iza­tion ef­forts to busi­ness de­vel­op­ment and clin­i­cal tri­als.

→ Astel­las has joined the glob­al mi­gra­tion of bio­phar­ma com­pa­nies to Cam­bridge, MA. The Japan­ese phar­ma has tak­en a lease out on space in Cam­bridge, ac­cord­ing to a re­port from the Boston Busi­ness Jour­nal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.